These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 16154259)
21. Is there a treatment advantage when paclitaxel and lovastatin are combined to dose anaplastic thyroid carcinoma cell lines? Chung YS; Cho S; Ryou HJ; Jee HG; Choi JY; Yoon K; Choi HJ; Lee KE; Suh YJ; Oh SK; Youn YK Thyroid; 2011 Jul; 21(7):735-44. PubMed ID: 21568723 [TBL] [Abstract][Full Text] [Related]
22. Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Dziba JM; Marcinek R; Venkataraman G; Robinson JA; Ain KB Thyroid; 2002 Dec; 12(12):1063-70. PubMed ID: 12593719 [TBL] [Abstract][Full Text] [Related]
23. Effects of Paclitaxel and combination of the drug with radiation therapy in an in vivo model of anaplastic thyroid carcinoma. Pushkarev VM; Starenki DV; Saenko VO; Tronko MD; Yamashita S Exp Oncol; 2011 Mar; 33(1):24-7. PubMed ID: 21423091 [TBL] [Abstract][Full Text] [Related]
24. Farnesyltransferase inhibitors reverse taxane resistance. Marcus AI; O'Brate AM; Buey RM; Zhou J; Thomas S; Khuri FR; Andreu JM; Díaz F; Giannakakou P Cancer Res; 2006 Sep; 66(17):8838-46. PubMed ID: 16951201 [TBL] [Abstract][Full Text] [Related]
25. Inhibition of corneal inflammation by the topical use of Ras farnesyltransferase inhibitors: selective inhibition of macrophage localization. Sonoda K; Sakamoto T; Yoshikawa H; Ashizuka S; Ohshima Y; Kishihara K; Nomoto K; Ishibashi T; Inomata H Invest Ophthalmol Vis Sci; 1998 Nov; 39(12):2245-51. PubMed ID: 9804132 [TBL] [Abstract][Full Text] [Related]
26. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies. Shalinsky DR; Brekken J; Zou H; Bloom LA; McDermott CD; Zook S; Varki NM; Appelt K Clin Cancer Res; 1999 Jul; 5(7):1905-17. PubMed ID: 10430098 [TBL] [Abstract][Full Text] [Related]
27. Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel. Tedjarati S; Baker CH; Apte S; Huang S; Wolf JK; Killion JJ; Fidler IJ Clin Cancer Res; 2002 Jul; 8(7):2413-22. PubMed ID: 12114447 [TBL] [Abstract][Full Text] [Related]
28. Increased expression of heat shock protein 70 in adherent ovarian cancer and mesothelioma following treatment with manumycin, a farnesyl transferase inhibitor. Hu W; Wu W; Yeung SC; Freedman RS; Kavanagh JJ; Verschraegen CF Anticancer Res; 2002; 22(2A):665-72. PubMed ID: 12014635 [TBL] [Abstract][Full Text] [Related]
29. Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Higashiyama T; Ito Y; Hirokawa M; Fukushima M; Uruno T; Miya A; Matsuzuka F; Miyauchi A Thyroid; 2010 Jan; 20(1):7-14. PubMed ID: 20025538 [TBL] [Abstract][Full Text] [Related]
30. Augmented growth inhibition of B16-BL6 melanoma by combined treatment with a selective matrix metalloproteinase inhibitor, MMI-166, and cytotoxic agents. Hojo K; Maki H; Sawada TY; Maekawa R; Yoshioka T Anticancer Res; 2002; 22(6A):3253-9. PubMed ID: 12530072 [TBL] [Abstract][Full Text] [Related]
31. Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma. Prichard CN; Kim S; Yazici YD; Doan DD; Jasser SA; Mandal M; Myers JN Laryngoscope; 2007 Apr; 117(4):674-9. PubMed ID: 17429874 [TBL] [Abstract][Full Text] [Related]
32. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma. Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627 [TBL] [Abstract][Full Text] [Related]
33. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes. Straight AM; Oakley K; Moores R; Bauer AJ; Patel A; Tuttle RM; Jimeno J; Francis GL Cancer Chemother Pharmacol; 2006 Jan; 57(1):7-14. PubMed ID: 16001179 [TBL] [Abstract][Full Text] [Related]
34. Modified radiosensitivity of pancreatic cancer xenografts by farnesyl protein transferase inhibitor and MEK inhibitor. Matsui Y; Goto M; Iwakawa M; Asano T; Kenmochi T; Imai T; Ochiai T Oncol Rep; 2003; 10(5):1525-8. PubMed ID: 12883735 [TBL] [Abstract][Full Text] [Related]
35. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140 [TBL] [Abstract][Full Text] [Related]
36. Therapeutic efficacy of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470) for human anaplastic thyroid carcinoma in nude mice. Hama Y; Shimizu T; Hosaka S; Sugenoya A; Usuda N Exp Toxicol Pathol; 1997 Aug; 49(3-4):239-47. PubMed ID: 9314059 [TBL] [Abstract][Full Text] [Related]
37. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice. Papadopoulou MV; Ji M; Ji X; Bloomer WD; Hollingshead MG Cancer Chemother Pharmacol; 2002 Dec; 50(6):501-8. PubMed ID: 12451478 [TBL] [Abstract][Full Text] [Related]
38. Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft. Weitman S; Mangold G; Marty J; Dexter D; Hilsenbeck S; Rake J; Juniewicz P; Von Hoff D Cancer Chemother Pharmacol; 1999; 43(5):402-8. PubMed ID: 10100596 [TBL] [Abstract][Full Text] [Related]
40. Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. Ain KB; Tofiq S; Taylor KD J Clin Endocrinol Metab; 1996 Oct; 81(10):3650-3. PubMed ID: 8855817 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]